"FDA awards GSK breakthrough status for relapsed osteosarcoma treatment" was originally created and published by ...

The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...

GSK plc GSK announced that the FDA has granted a Breakthrough Therapy Designation to its investigational B7-H3-targeted ...

GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital ...

GSK plc (GSK, GSK.L) said that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for GSK5764227, its ...

Working with a line of colon cancer cells, Korean researchers figured out a way to throw a few genetic switches to cause the ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter CSPC Pharmaceutical Group’s breakthrough therapy, SYS6010 ...

This story first appeared in Colorado Newsline. Coloradans will soon be able to take psychedelic mushrooms in a regulated ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...